Clinical Applications and Monte Carlo Validation of a fully integrated 3D dosimetry system

A comprehensive 3D dosimetry system consisting of the ClearView™ 3D dosimeter, VistaScan™ optical CT scanner, and VistaAce™ analysis software is commercially available and has the potential to be a strong verification tool with widespread applications. The clinical utility of this system (termed ClearView/Vista) has yet to be determined, and this work presents our first investigation. Clinical utility was evaluated using real patients' treatment plans: spine, head and neck, Single Isocenter Multi-Targets SRS (SIMT-SRS), and prostate cases. Independent validation was performed with a Monte Carlo-based dose calculation algorithm that was previously commissioned for clinical independent dose calculation. The analysis included line profile comparison (1D), isodose line comparison (2D), and global gamma analysis (3D). Results indicated a remarkable agreement between ClearView/Vista, the treatment planning system, and Monte Carlo, where gamma pass rates for all cases exceeded 94% even while using 2%2mm and a dose threshold of 10%. The ClearView/Vista 3D dosimetry system showed clinically acceptable accuracy and robust measurement and analysis in clinical settings.

Duke Scholars

Author Mark Oldham Radiation Oncology

Author Justus D Adamson Radiation Oncology